Dear Colleagues, it gives us great pleasure to invite you to the 5th International Symposium on Phaeochromocytoma and Paraganglioma at the Sofitel Sydney Wentworth, Australia from 30 August to 2 September 2017.

From each of the previous ISP meetings – in Bethesda, Cambridge, Paris and Kyoto – great advances in knowledge and treatments have been identified for the benefit of patients with these tumours. We encourage all the extraordinary scientists, clinicians and patients who have helped shape this rapidly emerging research field to continue their dialogue and present their discoveries in Sydney.

Phaeochromocytomas and paragangliomas (“pheo-para” tumours) represent unique windows into cancer biology due to their high heritability associated with genes in key oncogenic pathways, and energy metabolism. They can present dramatically with hypertension or catecholaminergic crisis (including heart failure and shock) and require high levels of clinical expertise for diagnosis, pre-operative medical treatments, surgery and post-operative follow-up for genetic counselling and management of recurrences. These tumours are also remarkable for their uptake and potential response to radiopharmaceuticals. This Symposium will therefore bring together all those with interests in Endocrinology and Endocrine Surgery, Head and Neck surgeons, Oncology, Hypertension, Nuclear Physicians, Geneticists and basic researchers in the fields of angiogenesis, hypoxia biology, oncology kinase signalling, metabolism and next-generation sequencing.

We expect the leading worldwide experts in the field to gather at ISP2017 to present their latest data, share clinical conundrums, showcase new therapeutic approaches, and develop strong international partnerships. Our Symposium promises to deliver new insights, better treatments, and hope for patients carrying the genetic susceptibility to pheo-para tumours.

The plenary sessions will deal with new advances in genetics (including next-generation sequencing), biochemical diagnosis and validation of new biomarkers, imaging (radiology and nuclear medicine), patient management, tumour biology, preclinical studies in animal models, therapeutic targets and new and future clinical trials.

Roderick Clifton-Bligh (Australia) and Judith Favier (France)
Co-Chairs, ISPP 2017


Supported By